EP1466598A3
(en)
*
|
1993-06-18 |
2007-06-27 |
Smithkline Beecham Corporation |
PDE-IV inhibitors
|
GB9312853D0
(en)
|
1993-06-22 |
1993-08-04 |
Euro Celtique Sa |
Chemical compounds
|
EP0714293A4
(en)
*
|
1993-07-30 |
1999-04-07 |
Smithkline Beecham Corp |
3-CYANO-3- (3,4-DISUBSTITUTED) PHENYLCYCLOHEXYL-1-CARBOXYLATE
|
US6013827A
(en)
*
|
1994-03-11 |
2000-01-11 |
Smithkline Beecham Corporation |
Compounds
|
GB9404706D0
(en)
*
|
1994-03-11 |
1994-04-27 |
Smithkline Beecham Corp |
Compounds
|
US5998428A
(en)
*
|
1995-05-31 |
1999-12-07 |
Smithkline Beecham Corporation |
Compounds and methods for treating PDE IV-related diseases
|
US20060019963A1
(en)
*
|
1994-06-17 |
2006-01-26 |
Smithkline Beecham Corporation |
Compounds
|
US5591776A
(en)
|
1994-06-24 |
1997-01-07 |
Euro-Celtique, S.A. |
Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
|
US5922751A
(en)
|
1994-06-24 |
1999-07-13 |
Euro-Celtique, S.A. |
Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
|
EP0799182A4
(en)
*
|
1994-12-23 |
1998-03-25 |
Smithkline Beecham Corp |
DIMERES 3.3- (DISUBSTITUTED) CYCLOHEXAN-1-OL AND RELATED COMPOUNDS
|
WO1996019994A1
(en)
*
|
1994-12-23 |
1996-07-04 |
Smithkline Beecham Corporation |
3,3-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
|
JPH10511398A
(ja)
*
|
1994-12-23 |
1998-11-04 |
スミスクライン・ビーチャム・コーポレイション |
4,4−(二置換)シクロヘキサン−1−カルボキシレート単量体および関連する化合物
|
EP0799187A4
(en)
*
|
1994-12-23 |
1998-03-25 |
Smithkline Beecham Corp |
4,4- (DISUBSTITUTED) CYCLOHEXAN-1-CARBONIC ACID DIMERS AND DERIVATIVES
|
EP0799181A4
(en)
*
|
1994-12-23 |
1998-03-25 |
Smithkline Beecham Corp |
DIMERES 3.3- (DISUBSTITUTED) CYCLOHEXANE-1-CARBOXYLATE AND RELATED COMPOUNDS
|
AU698028B2
(en)
*
|
1995-05-18 |
1998-10-22 |
Altana Pharma Ag |
Phenyldihydrobenzofurans
|
EP0828727B1
(de)
*
|
1995-05-18 |
2003-01-02 |
ALTANA Pharma AG |
Cyclohexyldihydrobenzofurane
|
US6166041A
(en)
|
1995-10-11 |
2000-12-26 |
Euro-Celtique, S.A. |
2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
|
US5891883A
(en)
*
|
1995-12-21 |
1999-04-06 |
Smithkline Beecham Corporation |
4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
|
US6075016A
(en)
|
1996-04-10 |
2000-06-13 |
Euro-Celtique S.A. |
6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
|
AP1147A
(en)
*
|
1996-05-03 |
2003-02-25 |
Pfizer |
Substituted indazole derivatives and related compounds.
|
EP0934307B1
(en)
|
1996-06-19 |
2011-04-27 |
Aventis Pharma Limited |
Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
|
BR9712782A
(pt)
*
|
1996-06-25 |
1999-12-07 |
Pfizer |
Derivados de indazol substituìdo e seu uso como inibidores de fosfodiesterose (pde) e fator de necrose de tumor (tnf)
|
US6054475A
(en)
*
|
1996-11-20 |
2000-04-25 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
Substituted dihydrobenzofuran-based phosphodiesterase 4 inhibitors useful for treating airway disorders
|
EP1524268B1
(en)
*
|
1997-02-12 |
2007-01-17 |
Smithkline Beecham Corporation |
Compounds and method for preparing sustituted 4-phenyl-4-cyanocyclohexanoic acids
|
AR012550A1
(es)
*
|
1997-02-12 |
2000-11-08 |
Smithkline Beecham Corp |
Metodo para preparar acidos 4-fenil-4-ciano-ciclohexanoicos sustituidos y compuestos intermediarios
|
DK1295869T3
(da)
*
|
1997-02-12 |
2005-11-21 |
Smithkline Beecham Corp |
Forbindelser og fremgangsmåde til fremstilling af substituerede 4-phenyl-4-cyanocyclohexansyrer
|
UA67753C2
(uk)
*
|
1997-10-10 |
2004-07-15 |
Смітклайн Бічам Корпорейшн |
Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот
|
EP1043994A4
(en)
*
|
1998-01-07 |
2002-09-11 |
Smithkline Beecham Corp |
METHOD OF TREATING MULTIPLE SCLEROSIS
|
UY25338A1
(es)
*
|
1998-01-07 |
2001-08-27 |
Smithkline Beecham Corp |
Método para tratar copd
|
US6172118B1
(en)
*
|
1998-04-14 |
2001-01-09 |
Smithkline Beecham Corporation |
Compounds
|
US6395273B1
(en)
|
1998-06-10 |
2002-05-28 |
Promega Corporation |
Prevention and treatment of inflammatory bowel disease
|
US7115557B2
(en)
*
|
1998-09-25 |
2006-10-03 |
Sciaticon Ab |
Use of certain drugs for treating nerve root injury
|
US7811990B2
(en)
*
|
1998-09-25 |
2010-10-12 |
Sciaticon Ab |
Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus
|
SE9803710L
(sv)
*
|
1998-09-25 |
2000-03-26 |
A & Science Invest Ab |
Användning av vissa substanser för behandling av nervrotsskador
|
US7906481B2
(en)
*
|
1998-09-25 |
2011-03-15 |
Sciaticon Ab |
Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
|
KR20010085852A
(ko)
|
1998-10-06 |
2001-09-07 |
도모따께 다께시 |
2,3-이치환 피리딘 유도체, 그의 제조방법, 그를 함유하는의약 조성물, 및 그의 제조용 중간체
|
AR028986A1
(es)
*
|
1999-02-23 |
2003-06-04 |
Smithkline Beecham Corp |
USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
|
US6419934B1
(en)
*
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
TNF modulators for treating neurological disorders associated with viral infection
|
AR035987A1
(es)
*
|
1999-03-01 |
2004-08-04 |
Smithkline Beecham Corp |
Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio
|
DZ3019A1
(fr)
*
|
1999-03-01 |
2005-05-20 |
Smithkline Beecham Corp |
Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
|
WO2000069820A1
(en)
*
|
1999-05-14 |
2000-11-23 |
Combichem, Inc. |
Cyclic amine derivatives and their uses
|
AR024076A1
(es)
*
|
1999-05-25 |
2002-09-04 |
Smithkline Beecham Corp |
Sales de cis-[4-ciano-4-(3-ciclopentiloxi-4-metoxifenil) ciclohexan-1-carboxilato]
|
ECSP003600A
(es)
*
|
1999-08-06 |
2002-03-25 |
Smithkline Beecham Corp |
Metodo para preparar acidos ciclohexano- carboxilicos
|
US6740765B1
(en)
*
|
1999-08-06 |
2004-05-25 |
Smithkline Beecham Corporation |
Method for preparing cyclohexane carboxylic acids
|
UY26268A1
(es)
*
|
1999-08-06 |
2001-01-31 |
Smithkline Beecham Corp |
Procedimiento para preparar acidos a traves de alfa-cloroep xi- esteres ley 17164 art 127
|
US20040220424A1
(en)
*
|
1999-08-06 |
2004-11-04 |
Smithkline Beecham Corporation |
Process for preparing acids via alpha-chloroepoxy esters
|
PT1212089E
(pt)
*
|
1999-08-21 |
2006-08-31 |
Altana Pharma Ag |
Combinacao sinergica de roflumilast e salmeterol
|
UY26333A1
(es)
*
|
1999-09-15 |
2001-07-31 |
Smithkline Beecham Corp |
Procedimiento e intermedios para preparar ácidos (4-ciano sustituido)- ciclohexanoicos
|
US20030050497A1
(en)
*
|
2002-07-11 |
2003-03-13 |
Webb Kevin Scott |
Process and intermediates for preparing a cyclohexylnitrile
|
AR029788A1
(es)
*
|
2000-01-12 |
2003-07-16 |
Smithkline Beecham Corp |
Procedimiento para reducir acidos ciclohexeno carboxilicos alfa,beta-insaturados, procedimiento para preparar acidos 4-nitrilo-4-aril-ciclohexanoicos, procedimiento para preparar acidos ciclohexeno carboxilicos alfa,beta-insaturados, y procedimientos para preparar intermediarios
|
HUP0204150A3
(en)
*
|
2000-01-26 |
2003-05-28 |
Smithkline Beecham Corp |
Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate, process for its preparation and pharmaceutical compositions containing the same
|
JP2003522142A
(ja)
*
|
2000-02-08 |
2003-07-22 |
スミスクライン・ビーチャム・コーポレイション |
炎症性疾患の治療法および治療用組成物
|
JP2004502643A
(ja)
*
|
2000-02-16 |
2004-01-29 |
ユニバーシティ・オブ・ネブラスカ・メディカル・センター |
線維症性疾患の治療法および治療用組成物
|
WO2001068600A2
(en)
*
|
2000-03-16 |
2001-09-20 |
Inflazyme Pharmaceuticals Limited |
Benzylated pde4 inhibitors
|
GB0011802D0
(en)
*
|
2000-05-16 |
2000-07-05 |
Smithkline Beecham |
Method for enhancing cognitive function
|
US20040005995A1
(en)
*
|
2001-07-26 |
2004-01-08 |
Edelson Jeffrey D |
Method for reducing exacerbations associated with copd
|
AU2001276497B2
(en)
|
2000-08-05 |
2005-04-07 |
Glaxo Group Limited |
17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
|
US20040224316A1
(en)
|
2000-08-10 |
2004-11-11 |
Tully Timothy P. |
Augmented cognitive training
|
US7250518B2
(en)
*
|
2001-01-31 |
2007-07-31 |
Pfizer Inc. |
Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
|
IL156460A0
(en)
*
|
2001-01-31 |
2004-01-04 |
Pfizer Prod Inc |
Ether derivatives useful as inhibitors of pde4 isozymes
|
JP2004520386A
(ja)
*
|
2001-01-31 |
2004-07-08 |
ファイザー・プロダクツ・インク |
Pde4アイソザイムの阻害剤として有用なニコチンアミドビアリール誘導体
|
PL365443A1
(en)
*
|
2001-01-31 |
2005-01-10 |
Pfizer Products Inc. |
Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
|
GB0103630D0
(en)
*
|
2001-02-14 |
2001-03-28 |
Glaxo Group Ltd |
Chemical compounds
|
JP4143413B2
(ja)
*
|
2001-03-22 |
2008-09-03 |
グラクソ グループ リミテッド |
β2−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
|
DE60229372D1
(de)
|
2001-04-30 |
2008-11-27 |
Glaxo Group Ltd |
Antiphlogistische 7.beta.-carbothioate esterderivate von androstan mit einer 17.alpha.-zyklischen estergruppe
|
KR20040007596A
(ko)
*
|
2001-05-23 |
2004-01-24 |
다나베 세이야꾸 가부시키가이샤 |
골절 치료 촉진용 조성물
|
CA2447618A1
(en)
*
|
2001-05-23 |
2002-11-28 |
Tanabe Seiyaku Co., Ltd. |
A composition for regenerative treatment of cartilage disease
|
PT1425001E
(pt)
*
|
2001-09-14 |
2009-02-18 |
Glaxo Group Ltd |
Derivados de fenetanolamina para o tratamento de doenças respiratórias
|
GB0217199D0
(en)
*
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicament dispenser
|
GB0201677D0
(en)
|
2002-01-25 |
2002-03-13 |
Glaxo Group Ltd |
Medicament dispenser
|
CN1649614A
(zh)
|
2002-02-22 |
2005-08-03 |
新河药品股份有限公司 |
活性剂传递系统和保护及施用活性剂的方法
|
GB0204719D0
(en)
*
|
2002-02-28 |
2002-04-17 |
Glaxo Group Ltd |
Medicinal compounds
|
DE60318193T2
(de)
*
|
2002-04-25 |
2008-12-04 |
Glaxo Group Ltd., Greenford |
Phenethanolaminderivate
|
US20030013905A1
(en)
*
|
2002-06-10 |
2003-01-16 |
Huang Guishu Kris |
Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid
|
GB0217196D0
(en)
*
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicament dispenser
|
GB0217198D0
(en)
*
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicament dispenser
|
GB0217225D0
(en)
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicinal compounds
|
ATE369353T1
(de)
*
|
2002-10-22 |
2007-08-15 |
Glaxo Group Ltd |
Medizinisch verwendbare arylethanolamin verbindungen
|
DE60320007T2
(de)
|
2002-10-28 |
2009-06-18 |
Glaxo Group Ltd., Greenford |
Phenthanolamin-Derivate zur Behandlung von Atemwegserkrankungen
|
US20060040981A1
(en)
*
|
2002-11-22 |
2006-02-23 |
Daniel Dube |
Use of phosphodiesterase-4 inhibitors as enhancers of cognition
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
GB0303396D0
(en)
*
|
2003-02-14 |
2003-03-19 |
Glaxo Group Ltd |
Medicinal compounds
|
MXPA05010373A
(es)
|
2003-04-01 |
2005-12-05 |
Applied Research Systems |
Inhibidores de fosfodiesterasas en infertilidad.
|
WO2005002626A2
(en)
*
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
WO2004098578A2
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
|
WO2004098606A1
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
Composition comprising a pde4 inhibitor and shuil-1r ii
|
OA13174A
(en)
|
2003-05-30 |
2006-12-13 |
Ranbaxy Lab Ltd |
Substituted pyrrole derivatives and their use as HMG-Co inhibitors.
|
GB0316290D0
(en)
*
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
DE10331798B4
(de)
*
|
2003-07-14 |
2012-06-21 |
Giesecke & Devrient Gmbh |
Sicherheitselement, Wertgegenstand, Transfermaterial und Herstellungsverfahren
|
GB0317374D0
(en)
|
2003-07-24 |
2003-08-27 |
Glaxo Group Ltd |
Medicament dispenser
|
US20050085430A1
(en)
*
|
2003-07-31 |
2005-04-21 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026883A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20090274676A1
(en)
*
|
2003-07-31 |
2009-11-05 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
GB0324654D0
(en)
*
|
2003-10-22 |
2003-11-26 |
Glaxo Group Ltd |
Medicinal compounds
|
GB0324886D0
(en)
*
|
2003-10-24 |
2003-11-26 |
Glaxo Group Ltd |
Medicinal compounds
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
AU2005227733A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Glaxo Group Limited |
Chemical process and new crystalline form
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
PE20060272A1
(es)
|
2004-05-24 |
2006-05-22 |
Glaxo Group Ltd |
(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
GB0418045D0
(en)
|
2004-08-12 |
2004-09-15 |
Glaxo Group Ltd |
Compounds
|
KR101061850B1
(ko)
|
2004-09-08 |
2011-09-02 |
삼성전자주식회사 |
박막 트랜지스터 표시판 및 그 제조방법
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
US20090124588A1
(en)
*
|
2005-01-10 |
2009-05-14 |
Glaxo Group Limited |
Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
|
WO2006072599A2
(en)
*
|
2005-01-10 |
2006-07-13 |
Glaxo Group Limited |
Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
|
JP2008526805A
(ja)
*
|
2005-01-11 |
2008-07-24 |
グラクソ グループ リミテッド |
ベータ−2アドレナリン作動薬のケイヒ酸塩
|
MY145281A
(en)
|
2005-03-25 |
2012-01-13 |
Glaxo Group Ltd |
Novel compounds
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
CA2625664C
(en)
|
2005-10-21 |
2016-01-05 |
Novartis Ag |
Human antibodies against il13 and therapeutic uses
|
CA2627599A1
(en)
|
2005-11-08 |
2007-05-18 |
Ranbaxy Laboratories Limited |
Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
|
PE20071068A1
(es)
|
2005-12-20 |
2007-12-13 |
Glaxo Group Ltd |
Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
CA2636324C
(en)
|
2006-01-06 |
2012-03-20 |
Sepracor Inc. |
Cycloalkylamines as monoamine reuptake inhibitors
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
JP5298008B2
(ja)
|
2006-04-20 |
2013-09-25 |
グラクソ グループ リミテッド |
新規化合物
|
PL2013211T3
(pl)
|
2006-04-21 |
2012-08-31 |
Novartis Ag |
Pochodne puryny do zastosowania jako agoniści receptora adenozyny A2A
|
JP2009537568A
(ja)
|
2006-05-19 |
2009-10-29 |
ヘリコン セラピューティクス,インコーポレイテッド |
認知および運動のリハビリテーションのためのホスホジエステラーゼ4インヒビター
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
AR061571A1
(es)
|
2006-06-23 |
2008-09-03 |
Smithkline Beecham Corp |
Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
|
ES2489265T3
(es)
|
2006-07-05 |
2014-09-01 |
Takeda Gmbh |
Asociación de inhibidores de la HMG-CoA reductasa atorvastatina o simvastatina con un inhibidor de la fosfodiesterasa 4, tal como roflumilast para el tratamiento de enfermedades pulmonares inflamatorias
|
US20100040609A1
(en)
*
|
2006-07-07 |
2010-02-18 |
Gorman James R |
Methods for preventing, postponing or improving the outcome of invasive spinal procedures
|
RU2009115954A
(ru)
|
2006-09-29 |
2010-11-10 |
Новартис АГ (CH) |
Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
|
RU2009120389A
(ru)
|
2006-10-30 |
2010-12-10 |
Новартис АГ (CH) |
Гетероциклические соединения в качестве противовоспалительных агентов
|
BRPI0720032A2
(pt)
*
|
2006-12-13 |
2013-12-17 |
Gilead Sciences Inc |
Composto e sais farmaceuticamente aceitáveis dos mesmos, processo, formulação de aerossol, método para a prevenção e tratamento de inflamação pulmonar ou broncoconstrição, e, uso de um composto.
|
KR101084787B1
(ko)
|
2007-01-10 |
2011-11-21 |
아이알엠 엘엘씨 |
채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
|
PE20081889A1
(es)
|
2007-03-23 |
2009-03-05 |
Smithkline Beecham Corp |
Indol carboxamidas como inhibidores de ikk2
|
US20090182035A1
(en)
*
|
2007-04-11 |
2009-07-16 |
Alcon Research, Ltd. |
Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
|
US20080254029A1
(en)
*
|
2007-04-11 |
2008-10-16 |
Alcon Research, Ltd. |
Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis
|
PL2155721T3
(pl)
|
2007-05-07 |
2011-07-29 |
Novartis Ag |
Związki organiczne
|
ES2393885T7
(es)
|
2007-06-04 |
2014-01-30 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
MX2009012644A
(es)
|
2007-06-05 |
2009-12-10 |
Sanofi Aventis |
Derivados de di(hetero)arilciclohexano, su preparacion, su uso y composiciones farmaceuticas que los comprenden.
|
US7943658B2
(en)
*
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
TW200920369A
(en)
*
|
2007-10-26 |
2009-05-16 |
Amira Pharmaceuticals Inc |
5-lipoxygenase activating protein (flap) inhibitor
|
TWI439462B
(zh)
|
2007-12-10 |
2014-06-01 |
Novartis Ag |
作為enac阻抑劑之螺環胍化合物
|
BRPI0906838A2
(pt)
|
2008-01-11 |
2015-07-14 |
Novartis Ag |
Pirimidinas como inibidores de quinase
|
SG190667A1
(en)
|
2008-05-23 |
2013-06-28 |
Panmira Pharmaceuticals Llc |
5-lipoxygenase-activating protein inhibitor
|
WO2009149279A2
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP2280959B1
(en)
|
2008-06-05 |
2012-04-04 |
Glaxo Group Limited |
4-amino-indazoles
|
WO2009147187A1
(en)
|
2008-06-05 |
2009-12-10 |
Glaxo Group Limited |
4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
|
CA2727196A1
(en)
|
2008-06-10 |
2009-12-17 |
Novartis Ag |
Organic compounds
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
SI2391366T1
(sl)
|
2009-01-29 |
2013-01-31 |
Novartis Ag |
Substituirani benzimidazoli za zdravljenje astrocitomov
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
US8524751B2
(en)
|
2009-03-09 |
2013-09-03 |
GlaxoSmithKline Intellecutual Property Development |
4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
|
EP2406249A1
(en)
|
2009-03-10 |
2012-01-18 |
Glaxo Group Limited |
Indole derivatives as ikk2 inhibitors
|
JP2012520845A
(ja)
|
2009-03-17 |
2012-09-10 |
グラクソ グループ リミテッド |
Itk阻害剤として使用されるピリミジン誘導体
|
EP2408458A1
(en)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20120016011A1
(en)
|
2009-03-19 |
2012-01-19 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
AU2010226604A1
(en)
|
2009-03-19 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
|
US20120029054A1
(en)
|
2009-03-19 |
2012-02-02 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
|
CA2756069A1
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1)gene expression using short interfering nucleic acid (sina)
|
EP2411516A1
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010111490A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
JP2012521763A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたシグナル伝達性転写因子1(STAT1)遺伝子発現のRNA干渉媒介性阻害
|
WO2010111468A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
US8399436B2
(en)
|
2009-04-24 |
2013-03-19 |
Glaxo Group Limited |
N-pyrazolyl carboxamides as CRAC channel inhibitors
|
US20120035237A1
(en)
|
2009-04-24 |
2012-02-09 |
Diane Mary Coe |
Pyrazole and triazole carboxamides as crac chann el inhibitors
|
DK2899191T3
(da)
|
2009-04-30 |
2017-11-13 |
Glaxo Group Ltd |
Oxazol-substituerede indazoler som pi3-kinaseinhibitorer
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
KR20120089643A
(ko)
|
2009-08-12 |
2012-08-13 |
노파르티스 아게 |
헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
|
MY162604A
(en)
|
2009-08-17 |
2017-06-30 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
WO2011020861A1
(en)
|
2009-08-20 |
2011-02-24 |
Novartis Ag |
Heterocyclic oxime compounds
|
WO2011041640A1
(en)
*
|
2009-10-01 |
2011-04-07 |
Alcon Research, Ltd. |
Olopatadine compositions and uses thereof
|
EP2490687A1
(en)
|
2009-10-22 |
2012-08-29 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
WO2011067364A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Novel compounds
|
WO2011067366A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Indazole derivatives as pi 3 - kinase inhibitors
|
JP2013512879A
(ja)
|
2009-12-03 |
2013-04-18 |
グラクソ グループ リミテッド |
Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体
|
EP2512438B1
(en)
|
2009-12-16 |
2017-01-25 |
3M Innovative Properties Company |
Formulations and methods for controlling mdi particle size delivery
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
JP5876051B2
(ja)
|
2010-09-08 |
2016-03-02 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
|
PL2614058T3
(pl)
|
2010-09-08 |
2015-12-31 |
Glaxosmithkline Ip Dev Ltd |
Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
WO2012052459A1
(en)
|
2010-10-21 |
2012-04-26 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
EP2630126B1
(en)
|
2010-10-21 |
2015-01-07 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, immune and inflammatory conditions
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
EP2678338B1
(en)
|
2011-02-25 |
2015-09-09 |
Novartis AG |
Pyrazolo[1,5-a]pyridines as trk inhibitors
|
US9580471B2
(en)
|
2011-03-01 |
2017-02-28 |
Synergy Pharmaceuticals, Inc. |
Process of preparing guanylate cyclase C agonists
|
EP2683716A1
(en)
|
2011-03-11 |
2014-01-15 |
Glaxo Group Limited |
Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
EP2755976B1
(en)
|
2011-09-15 |
2018-07-18 |
Novartis AG |
6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
CN103946221B
(zh)
|
2011-09-16 |
2016-08-03 |
诺华股份有限公司 |
用于治疗囊性纤维化的杂环化合物
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038390A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
JP6130391B2
(ja)
|
2011-11-23 |
2017-05-17 |
インテリカイン, エルエルシー |
Mtor阻害剤を使用する強化された治療レジメン
|
WO2013084182A1
(en)
|
2011-12-08 |
2013-06-13 |
Glenmark Pharmaceuticals S.A. |
Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
AU2013243097A1
(en)
|
2012-04-03 |
2014-10-09 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use
|
JP6499591B2
(ja)
|
2013-02-25 |
2019-04-10 |
シナジー ファーマシューティカルズ インコーポレイテッド |
結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
JP2016512835A
(ja)
|
2013-03-15 |
2016-05-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤の組み合わせ及びそれらの使用
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
RS65632B1
(sr)
|
2013-06-05 |
2024-07-31 |
Bausch Health Ireland Ltd |
Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
|
KR20220147691A
(ko)
|
2013-08-09 |
2022-11-03 |
알데릭스, 인코포레이티드 |
인산염 수송을 억제하기 위한 화합물 및 방법
|
EP3046563B1
(en)
|
2013-09-22 |
2019-05-29 |
Calitor Sciences, LLC |
Substituted aminopyrimidine compounds as pi3-kinase inhibitors
|
AU2014336250A1
(en)
|
2013-10-17 |
2016-04-14 |
Glaxosmithkline Intellectual Property Development Limited |
PI3K inhibitor for treatment of respiratory disease
|
RU2016112266A
(ru)
|
2013-10-17 |
2017-11-20 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Ингибитор PI3K для лечения респираторного заболевания
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
EP3122730B1
(en)
|
2014-03-28 |
2020-03-25 |
Calitor Sciences, LLC |
Substituted heteroaryl compounds and methods of use
|
WO2015162456A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
BR112016023967A2
(pt)
|
2014-04-24 |
2017-08-15 |
Novartis Ag |
derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
|
CA2945212A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
EA201692111A1
(ru)
|
2014-05-12 |
2017-08-31 |
Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед |
Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
BR112017001695A2
(pt)
|
2014-07-31 |
2017-11-21 |
Novartis Ag |
terapia de combinação
|
US9938257B2
(en)
|
2015-09-11 |
2018-04-10 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
EP3165224A1
(en)
|
2015-11-09 |
2017-05-10 |
Albert-Ludwigs-Universität Freiburg |
Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
|
WO2017089347A1
(en)
|
2015-11-25 |
2017-06-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
|
GB201602527D0
(en)
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
WO2018029126A1
(en)
|
2016-08-08 |
2018-02-15 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
WO2018094392A1
(en)
|
2016-11-21 |
2018-05-24 |
Lupin Inc. |
Medicament dispenser
|
GB201706102D0
(en)
|
2017-04-18 |
2017-05-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
GB201712081D0
(en)
|
2017-07-27 |
2017-09-13 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
EP3710006A4
(en)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
|
WO2019143874A1
(en)
|
2018-01-20 |
2019-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
WO2019195711A1
(en)
|
2018-04-06 |
2019-10-10 |
Lupin Inc. |
Medicament dispenser
|
WO2019198779A1
(ja)
*
|
2018-04-11 |
2019-10-17 |
三菱瓦斯化学株式会社 |
1,4-シクロヘキサンジカルボン酸誘導体、1,4-ジシアノシクロヘキサン、及び1,4-ビス(アミノメチル)シクロヘキサンの製造方法
|
WO2020058823A1
(en)
|
2018-09-17 |
2020-03-26 |
Lupin, Inc. |
Dose indicator assembly for a medicament dispenser
|
WO2020237096A1
(en)
|
2019-05-21 |
2020-11-26 |
Ardelyx, Inc. |
Combination for lowering serum phosphate in a patient
|
CN113891744A
(zh)
|
2019-06-10 |
2022-01-04 |
诺华股份有限公司 |
用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物
|
KR20220052934A
(ko)
|
2019-08-28 |
2022-04-28 |
노파르티스 아게 |
치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
|
CN115916305A
(zh)
|
2020-03-25 |
2023-04-04 |
陆品公司 |
多载体药物分配器
|
JP2023519585A
(ja)
|
2020-03-26 |
2023-05-11 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
ウイルス感染を予防または治療するカテプシン阻害剤
|
WO2022020506A1
(en)
|
2020-07-23 |
2022-01-27 |
Lupin Inc. |
Dose counter assemblies for medicament dispensers
|